Company profile
Genomenon, Inc
Genomic intelligence for clinical diagnostics and precision medicine development
- Industry
- Biotechnology Research
- Employees
- 136
- Headquarters
- Ann Arbor, Michigan
- Founded
- 2014
- LinkedIn followers
- 10,691
- Office locations
- 1
Genomenon, Inc company summary
Genomenon, Inc is a company in the Biotechnology Research industry, headquartered in Ann Arbor, Michigan, founded in 2014. On LinkedIn the company has around 136 employees and 10,691 followers. Its listed specialties include Bioinformatics, Genomics, Whole Exome Sequencing, Whole Genome Sequencing, Genetics.
What technology does Genomenon, Inc use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Genomenon, Inc
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is published. It is peer-reviewed. It is buried in 39 million biomedical articles, locked behind paywalls, hidden in tables, appendices, and supplemental datasets that most researchers and clinicians never find. Missing that evidence has consequences. Rare disease patients go undiagnosed. Cancer patients miss life-saving treatments built around variants their lab could not classify. Drug programs commit to development paths on incomplete data. Clinical trials miss eligible patients. Label expansions get left on the table. Genomenon was founded to close that gap. Fit-for-purpose AI-powered search indexes the 11.2 million full-text papers and 3.7 million supplemental tables and datasets standard tools miss. Eighty expert scientific curators review and validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. The difference is measured. Loxo@Lilly used Genomenon to expand the Retevmo label by 73 variants, broadening medullary thyroid cancer eligibility by 15%. Amicus added 1,300+ GLA variants for Fabry disease, with 534 deposited in ClinVar, expanding the Galafold label by 15 variants. In a published head-to-head, Genomenon identified 83% more PRKAG2 cardiomyopathy patients than ChatGPT plus OpenEvidence. More than 250 diagnostic labs and 75 biopharma programs rely on Genomenon today as the evidence layer behind precision medicine. We find the Real-World Evidence that changes rare disease and cancer patients’ lives.
Specialties
Where is Genomenon, Inc located?
Genomenon, Inc lists 1 location.
Compare companies similar to Genomenon, Inc
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Genomenon, Inc genomenon.com | Biotechnology Research | 136 | 2014 | Ann Arbor, Michigan |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Genomenon, Inc
What does Genomenon, Inc do?
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is published. It is peer-reviewed. It is buried in 39 million biomedical articles, locked behind paywalls, hidden in tables, appendices, and supplemental datasets that most researchers and clinicians never find. Missing that evidence has consequences. Rare disease patients go undiagnosed. Cancer patients miss life-saving treatments built around variants their lab could not classify. Drug programs commit to development paths on incomplete data. Clinical trials miss eligible patients. Label expansions get left on the table. Genomenon was founded to close that gap. Fit-for-purpose AI-powered search indexes the 11.2 million full-text papers and 3.7 million supplemental tables and datasets standard tools miss. Eighty expert scientific curators review and validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. The difference is measured. Loxo@Lilly used Genomenon to expand the Retevmo label by 73 variants, broadening medullary thyroid cancer eligibility by 15%. Amicus added 1,300+ GLA variants for Fabry disease, with 534 deposited in ClinVar, expanding the Galafold label by 15 variants. In a published head-to-head, Genomenon identified 83% more PRKAG2 cardiomyopathy patients than ChatGPT plus OpenEvidence. More than 250 diagnostic labs and 75 biopharma programs rely on Genomenon today as the evidence layer behind precision medicine. We find the Real-World Evidence that changes rare disease and cancer patients’ lives.
How many employees does Genomenon, Inc have?
Genomenon, Inc has around 136 employees on LinkedIn.
Where is Genomenon, Inc headquartered?
Genomenon, Inc is headquartered in Ann Arbor, Michigan.
When was Genomenon, Inc founded?
Genomenon, Inc was founded in 2014.
Build a lead list from companies like Genomenon, Inc
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.